Cameron Health Inc.
This article was originally published in Start Up
Executive Summary
Cameron Health believes that the market for implantable cardiac defibrillators (ICDs) is underpenetrated because of the complexity involved in implanting and programming current devices. The company's cardiologist founders created an implantable device that effectively terminates ventricular defibrillation, without using leads that contact the heart directly. Heart leads are the weakest link of current devices, since they can break, become dislodged, or incur infection, Cameron's Health device, which can be implanted subcutaneously in a ten minute procedure should help electrophysiologists handle a higher volume of patients and enable cardiologists to get a share of the procedures as well.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.